A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine

Pharmacopsychiatry. 2008 Jan;41(1):17-23. doi: 10.1055/s-2007-992148.

Abstract

Introduction: The aim of this study was to evaluate the efficacy of a psychoeducational program (PEP) for weight control in patients who had experienced an increase of body weight during treatment with olanzapine.

Methods: Eligible patients were randomised to the PEP (Group 1) or to no intervention (Group 2) and continued on olanzapine. After 12 weeks, the PEP was also started in Group 2 and continued in Group 1, up to week 24. Body weight was measured every month. Other measures included quality of life, and change in plasma glucose and lipids levels.

Results: Patients in Group 1 (n=15) had a mean weight loss of 3.6 kg at week 12 and 4.5 kg at week 24 (p<0.01 at both times, p<0.01 between groups at week 12), while those in Group 2 (n=18) had no changes at week 12 and a significant weight loss at week 24 (-3.6 kg from week 12, p<0.01). Changes of BMI paralleled those of body weight. Quality of life (Q-LES-Q-SF categorisation) and functioning (GAF) significantly improved in the total population at endpoint (p<0.01). No significant changes were observed in fasting glucose and lipid profile, while insulin levels significantly decreased from baseline to endpoint in both groups (p<0.05). HOMA index and hepatic insulin sensitivity improved, too.

Discussion: Patients with increased BMI during treatment with olanzapine experienced significant weight and BMI loss following a structured psychoeducational program.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Analysis of Variance
  • Antipsychotic Agents / adverse effects*
  • Benzodiazepines / adverse effects*
  • Cognitive Behavioral Therapy / methods*
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Male
  • Mental Disorders / complications
  • Mental Disorders / drug therapy
  • Middle Aged
  • Obesity / chemically induced*
  • Obesity / therapy*
  • Olanzapine
  • Psychiatric Status Rating Scales / statistics & numerical data
  • Time Factors
  • Weight Gain / drug effects*

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Olanzapine